Thorne HealthTech Reports Second Quarter 2023 Results
- 33.1% increase in net sales to $72.7 million
- 35.7% growth in gross profit to $40.6 million
- Raised full-year guidance for net sales and gross margin
- None.
Record Net Sales With Growth of
Second Quarter Highlights:
- Net sales grew
33.1% year-over-year to , with direct-to-consumer ("DTC") sales growth of$72.7 million 39.3% - Gross profit grew
35.7% year-over-year to ; gross profit as a % of net sales increased year-over-year to$40.6 million 55.9% . - Net income attributable to Thorne HealthTech, Inc. of
; adjusted EBITDA1 of$4.4 million $12.5 million - Diluted earnings per share ("EPS") of
; adjusted diluted EPS1 of$0.08 $0.15 - Raises midpoints of full-year 2023 guidance ranges for each of net sales and gross profit as a % of net sales, resulting in updated guidance ranges for net sales of
to$285 million and gross profit as a % of net sales of$290 million 50% to52% - Raises full-year 2023 guidance range for adjusted EPS1 to
to$0.26 based on updated estimated applicable statutory tax rates in the second quarter$0.32 - At-home blood sampling device earned CE (Conformite Europeenne) Mark certification in the European Union
1Adjusted EBITDA and adjusted diluted EPS are non-GAAP measures. Important disclosures about, and reconciliations of, non-GAAP measures to their most directly comparable GAAP measures, including adjusted EBITDA, adjusted net income and adjusted diluted earnings EPS are provided in the "Non-GAAP Financial Measures" section of this press release.
"The Company delivered another strong financial performance in the second quarter, achieving record net sales and adjusted EBITDA," said Paul Jacobson, Thorne HealthTech's chairman and CEO. "Robust demand for our premium wellness offerings resulted in 33 percent sales growth, with favorable gross margin contributions from direct-to-consumer channel strength, pricing, product rationalization, and lower overhead. Looking ahead to the second half of the year, with our plant expansion on track, the core business is well positioned for continued momentum as we drive innovation into the product portfolio and increase brand awareness through our recently launched marketing campaign. As a result, we are raising the midpoints of our guidance ranges for sales and gross margin."
Net Sales
The following tables provide a summary of sales by channel for the three and six months ended June 30, 2023, compared to the three and six months ended June 30, 2022:
Three Months Ended June 30, | ||||||||||||||||||||||||
Amounts | Year-Over-Year | As % of Net Sales | ||||||||||||||||||||||
2023 | 2022 | $ Change | % Change | 2023 | 2022 | |||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
DTC | $ | 36,800 | $ | 26,425 | $ | 10,375 | 39.3 | % | 50.6 | % | 48.4 | % | ||||||||||||
Professional/B2B (1) | 35,915 | 28,216 | 7,699 | 27.3 | % | 49.4 | % | 51.6 | % | |||||||||||||||
Net Sales (2) | $ | 72,715 | $ | 54,641 | $ | 18,074 | 33.1 | % | 100.0 | % | 100.0 | % | ||||||||||||
Six Months Ended June 30, | ||||||||||||||||||||||||
Amounts | Year-Over-Year | As % of Net Sales | ||||||||||||||||||||||
2023 | 2022 | $ Change | % Change | 2023 | 2022 | |||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
DTC | $ | 70,617 | $ | 50,416 | $ | 20,201 | 40.1 | % | 51.2 | % | 46.4 | % | ||||||||||||
Professional/B2B (1) | 67,336 | 58,255 | 9,081 | 15.6 | % | 48.8 | % | 53.6 | % | |||||||||||||||
Net Sales (2) | $ | 137,953 | $ | 108,671 | $ | 29,282 | 26.9 | % | 100.0 | % | 100.0 | % |
(1) | "Professional" generally means the Company's network of health professionals; and "B2B" generally means business-to-business customers. |
(2) | As disclosed in prior quarters, we reclassified certain amounts in the condensed consolidated statements of operations as a result of certain immaterial classification errors related to prior interim periods. For the three months ended June 30, 2022, such reclassification reflected a decrease of |
The following table provides a summary of the Company's annual life-time value ("LTV") to customer acquisition cost ("CAC") ratio for the three and six months ended June 30, 2023, compared to the three and six months ended June 30, 2022:
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||
2023 | 2022 | 2023 | 2022 | ||||||
LTV to CAC (3) | 4.0x | 1.8x | 3.7x | 2.7x |
(3) | Refer to the "Key Financial and Operating Data" section below. |
As of June 30, 2023, the number of active subscriptions on Thorne.com grew
Cost of Sales and Gross Profit
The following tables provide a summary of cost of sales and gross profit for the three and six months ended June 30, 2023, compared to the three and six months ended June 30, 2022:
Three Months Ended June 30, | ||||||||||||||||||||||||
Amounts | Year-Over-Year | As % of Net Sales | ||||||||||||||||||||||
2023 | 2022 | $ Change | % Change | 2023 | 2022 | |||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Net sales | $ | 72,715 | $ | 54,641 | $ | 18,074 | 33.1 | % | 100.0 | % | 100.0 | % | ||||||||||||
Cost of sales | 32,077 | 24,704 | 7,373 | 29.8 | % | 44.1 | % | 45.2 | % | |||||||||||||||
Gross profit | $ | 40,638 | $ | 29,937 | $ | 10,701 | 35.7 | % | 55.9 | % | 54.8 | % | ||||||||||||
Six Months Ended June 30, | ||||||||||||||||||||||||
Amounts | Year-Over-Year | As % of Net Sales | ||||||||||||||||||||||
2023 | 2022 | $ Change | % Change | 2023 | 2022 | |||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Net sales | $ | 137,952 | $ | 108,671 | $ | 29,281 | 26.9 | % | 100.0 | % | 100.0 | % | ||||||||||||
Cost of sales | 63,041 | 49,255 | 13,786 | 28.0 | % | 45.7 | % | 45.3 | % | |||||||||||||||
Gross profit | $ | 74,911 | $ | 59,416 | $ | 15,495 | 26.1 | % | 54.3 | % | 54.7 | % |
For the three and six months ended June 30, 2023, the increase in gross profit as a percentage of net sales was primarily from (i) increase in net sales and (ii) lower overhead costs. These increases were partially offset by certain higher cost of raw material as we sell through our higher priced inventory.
Operating Expenses
The following tables provide a summary of selected operating expenses for the three and six months ended June 30, 2023, compared to the three and six months ended June 30, 2022:
Three Months Ended June 30, | ||||||||||||||||||||||||
Amounts | Year-Over-Year | As % of Net Sales | ||||||||||||||||||||||
2023 | 2022 | $ Change | % Change | 2023 | 2022 | |||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Research and development | $ | 1,506 | $ | 1,744 | $ | (238) | -13.6 | % | 2.1 | % | 3.2 | % | ||||||||||||
Marketing | 10,038 | 15,841 | (5,803) | -36.6 | % | 13.8 | % | 29.0 | % | |||||||||||||||
Selling, general and administrative | 22,471 | 18,505 | 3,966 | 21.4 | % | 30.9 | % | 33.9 | % | |||||||||||||||
Six Months Ended June 30, | ||||||||||||||||||||||||
Amounts | Year-Over-Year | As % of Net Sales | ||||||||||||||||||||||
2023 | 2022 | $ Change | % Change | 2023 | 2022 | |||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Research and development | $ | 3,278 | $ | 3,711 | $ | (433) | -11.7 | % | 2.4 | % | 3.4 | % | ||||||||||||
Marketing | 18,976 | 20,642 | (1,666) | -8.1 | % | 13.8 | % | 19.0 | % | |||||||||||||||
Selling, general and administrative | 46,048 | 36,433 | 9,615 | 26.4 | % | 33.4 | % | 33.5 | % |
The decrease in marketing and marketing expense for three and six months ended June 30, 2023 was in line with planned spending targets, ahead of a significant marketing campaign that started in late July, which is intended to increase brand awareness and highlight the long-term value of the benefits of Thorne's portfolio of offerings. The increase in selling, general and administrative expenses for three and six months ended June 30, 2023 was primarily due to (i) increased selling costs associated with the increase in net sales and (ii) increased employee compensation costs.
Net Income and Diluted EPS
The following tables provide a summary of net income attributable to Thorne HealthTech, Inc., adjusted EBITDA, adjusted net income (loss), diluted EPS and adjusted diluted EPS for the three and six months ended June 30, 2023, compared to the three and six months ended June 30, 2022:
Three Months Ended June 30, | ||||||||||||
Amounts | Year-Over-Year | |||||||||||
2023 | 2022 | $ Change | ||||||||||
(dollars in thousands, except per share amounts) | ||||||||||||
Net income (loss) attributable to Thorne HealthTech, Inc. | $ | 4,446 | $ | (5,591) | $ | 10,037 | ||||||
Adjusted EBITDA | 12,535 | (1,336) | 13,870 | |||||||||
Adjusted net income (loss) | 8,048 | (2,602) | 10,650 | |||||||||
Diluted EPS | $ | 0.08 | $ | (0.11) | $ | 0.19 | ||||||
Adjusted diluted EPS | $ | 0.15 | $ | (0.05) | $ | 0.20 | ||||||
Six Months Ended June 30, | ||||||||||||
Amounts | Year-Over-Year | |||||||||||
2023 | 2022 | $ Change | ||||||||||
(dollars in thousands, except per share amounts) | ||||||||||||
Net income (loss) attributable to Thorne HealthTech, Inc. | $ | 4,044 | $ | (612) | $ | 4,655 | ||||||
Adjusted EBITDA | 18,655 | 7,425 | 11,230 | |||||||||
Adjusted net income | 11,130 | 4,048 | 7,082 | |||||||||
Diluted EPS | $ | 0.08 | $ | (0.01) | $ | 0.09 | ||||||
Adjusted diluted EPS | $ | 0.21 | $ | 0.08 | $ | 0.13 |
Financial Position
As of June 30, 2023, the Company had
Financial Guidance
The Company is raising the midpoints of its full-year 2023 guidance ranges for each of net sales and gross profit as a percentage of net sales. The Company is also raising its full-year 2023 guidance range for adjusted EPS based on updating its estimate of applicable statutory rates during the second quarter, as described below. The Company is reaffirming its prior guidance range for adjusted EBITDA. Accordingly, the following table presents the Company's updated full-year 2023 guidance and the corresponding growth rates over full-year 2022 results at the low and high ends of the guidance ranges for each measure:
Updated Full-Year Guidance | Prior Guidance | ||||||
Low - High | Low - High (Y/Y%) | Low - High | |||||
Net sales | |||||||
Gross profit as a % of net sales | — | ||||||
Adjusted EBITDA | |||||||
Adjusted diluted EPS | ( |
The Company's updated full-year guidance assumes the following:
- Marketing expenses of between
14% and15% of net sales, an increase from the prior range of between13% and15% , with the highest spend expected during the third quarter in connection with the Company's recently launched marketing campaign - Adjusted diluted EPS guidance also assumes: (i) depreciation and amortization of approximately
2.5% of net sales, with cost recognition expected to gradually increase during the year from the facility expansion, (ii) interest expense of approximately1% of sales, (iii) an updated estimated full-year adjusted tax rate of22.9% , a reduction from the prior estimate of26% and (iv) diluted weighted-average shares outstanding of 54 million as of December 31, 2023 - Capital expenditures of between
to$35 million primarily related to our plant expansion$38 million
Webcast and Conference Call Details
The Company will host a conference call on Tuesday, August 8, 2023, at 5:00 p.m. (
In addition, the conference call can be accessed over the phone by dialing +1 888 300 4150 (
About Thorne HealthTech
Thorne HealthTech is a leader in developing innovative solutions for delivering personalized approaches to health and wellness. As a science-driven wellness company that empowers individuals with the support, education, and solutions they need to achieve healthy aging – living healthier longer – Thorne utilizes testing and data to create improved product efficacy and to deliver personalized solutions to consumers, health professionals, and corporations. Predicated on the power of the individual, Thorne leverages artificial intelligence models to provide insights and personalized data, products, and services that help individuals take a proactive and actionable approach to improve and maintain their health over a lifetime. Thorne is the only supplement manufacturer that collaborates with Mayo Clinic on health and wellness research and content, and is trusted by more than five million customers, 47,000+ health-care professionals, thousands of professional athletes, more than 100 professional sports teams, and multiple
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this news release, including, without limitation, statements regarding the conditions of our industry, our future results of operations and financial position, business strategy, development plans, expected research and development costs, regulatory strategy, product and service development, sales and marketing activities, international expansion efforts, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "guidance," "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in this news release include, but are not limited to, statements regarding financial guidance, market opportunity, ability to penetrate the market, expanded product offerings and expectations for growth. We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements are current only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions described in the section titled "Risk Factors" and elsewhere in Thorne HealthTech's filings made with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed on March 31, 2023 and Quarterly Report on Form 10-Q, which we plan to file on or about August 9, 2023, and other SEC filings, copies of which are available free of charge on the SEC website at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.
Key Financial and Operating Data
Amounts reported in thousands within this press release are computed based on the amounts in whole dollars. As a result, the sum of the components reported in thousands may not equal the amounts reported in whole dollars due to rounding. Percentage changes presented are calculated from the underlying numbers in whole dollars.
To provide investors with additional information regarding its financial results, the Company has provided certain key financial and operating data metrics in this press release, including annual life-time value ("LTV"), customer acquisition costs ("CAC"), LTV to CAC ratio and number of subscriptions.
We define annual LTV to CAC ratio as LTV from a specific calendar year divided by the CAC of that same year. Annual LTV is defined as the average gross contribution per customer purchasing product on Thorne.com and on Amazon.com via our authorized reseller ("DTC Customer") within a particular calendar year divided by one less the customer retention rate ("Churn Rate") during the same period. Average gross contribution is defined as the cumulative revenue from our DTC Customers during a calendar year less the cost of goods divided by the number of purchasing DTC Customers in the same period. To arrive at the annual LTV for a particular calendar year, we divide the average gross contribution by that year's Churn Rate. Annual CAC is defined as the total advertising and marketing expenses, inclusive of cooperative advertising costs treated as a reduction of net sales, less headcount and associated benefit expenses as well as costs attributed to value-in-kind, product samples, and sponsorships for professional and B2B customers, divided by the number of DTC Customers who placed their first order during that same calendar year. We view the annual LTV to CAC ratio as a key indicator for marketing efficiency.
The Company defines subscriptions as orders resulting from DTC Customers opting into automatic refills or orders that are recurring on Thorne.com and Amazon.com. Subscription programs on both platforms offer automatic ordering, payment and delivery of the products to a customer's doorstep.
Non-GAAP Financial Measures
To provide investors with additional information regarding its financial results, the Company has provided certain financial measures that are not recognized under
The Company calculates EBITDA, a non-GAAP financial measure, as net income or loss excluding depreciation and amortization, interest expense, net and income taxes. EBITDA margin represents EBITDA as a percentage of net sales. The Company calculates adjusted EBITDA, a non-GAAP financial measure, by further excluding non-cash items for stock-based compensation expenses, non-cash lease expense, change in fair value of warrant liability, loss on Drawbridge step acquisition, loss on Drawbridge Transaction, guarantee fees, income or loss from equity interests in unconsolidated affiliates and transaction-related costs. Adjusted EBITDA margin represents Adjusted EBITDA as a percentage of net sales. The Company calculates adjusted net income or loss, a non-GAAP financial measure, as net income or loss excluding (i) stock-based compensation expenses, non-cash lease expense, change in fair value of warrant liability, income or loss from equity in unconsolidated affiliates, and transaction-related costs and (ii) utilizing an adjusted provision for income taxes based on the Company's estimate of applicable statutory rates.
EBITDA, EBITDA margin, adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss) and adjusted diluted earnings (loss) per share should be viewed as measures of operating performance that are supplements to, and not substitutes for, operating income or loss, net income or loss and other GAAP measures of income and loss. The Company has included EBITDA, EBITDA margin, adjusted EBITDA, adjusted EBITDA margin, adjusted net income or loss and adjusted diluted earnings (loss) per share in this press release because they are key measures used by the Company's management to evaluate and compare the Company's financial and operational performance over multiple periods, identifying trends affecting the Company's business, formulating business plans and making strategic decisions. In particular, the exclusion of certain expenses or income in calculating adjusted EBITDA and adjusted net income (loss) facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain non-recurring variable charges. In addition, the Company believes that providing each of EBITDA and adjusted EBITDA and adjusted net income or loss, together with a reconciliation of net income or loss to each such measure, helps investors make comparisons between Thorne HealthTech and other companies that may have different capital structures, different tax rates and different forms of employee compensation. Each of EBITDA, EBITDA margin, adjusted EBITDA, adjusted EBITDA margin, adjusted net income or loss and adjusted diluted earnings (loss) per share has inherent limitations because of the excluded items, and may not be directly comparable to similarly titled metrics used by other companies.
The Company has not reconciled the forward-looking adjusted EBITDA and adjusted diluted EPS guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), certain fair value measurements, transaction-related costs and integration, tax items and others that may arise during the year, each of which are potential adjustments to future earnings. The Company expects the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
Thorne HealthTech, Inc. Condensed Consolidated Balance Sheets (unaudited) | ||||||||
June 30, | December 31, | |||||||
2023 | 2022 | |||||||
Assets | ||||||||
Current Assets | ||||||||
Cash and cash equivalents | $ | 17,093,556 | $ | 36,024,847 | ||||
Restricted cash | 15,201,129 | 4,900,000 | ||||||
Accounts receivable, net | 25,406,854 | 14,367,785 | ||||||
Related party receivables | 159,528 | 68,731 | ||||||
Inventories, net | 71,685,307 | 58,643,928 | ||||||
Prepaid expenses and other current assets | 5,919,447 | 2,615,593 | ||||||
Total current assets | 135,465,821 | 116,620,884 | ||||||
Long-term Assets | ||||||||
Property and equipment, net | 65,324,802 | 49,176,844 | ||||||
Operating lease right-of-use assets, net | 33,588,576 | 17,546,240 | ||||||
Finance lease right-of-use assets, net | 2,734,096 | 3,143,592 | ||||||
Intangible assets, net | 14,887,063 | 11,830,249 | ||||||
Goodwill | 20,041,040 | 20,041,040 | ||||||
Investments | 1,400,000 | 1,400,000 | ||||||
Equity-method investments | 981,726 | 942,501 | ||||||
Other related party receivables | — | 153,556 | ||||||
Deferred tax assets | 6,942,187 | 7,782,187 | ||||||
Other assets | 1,162,138 | 1,166,928 | ||||||
Total assets | $ | 282,527,449 | $ | 229,804,021 |
Thorne HealthTech, Inc. Condensed Consolidated Balance Sheets (unaudited) | ||||||||
June 30, | December 31, | |||||||
2023 | 2022 | |||||||
Liabilities, Convertible Preferred Stock and Stockholders' Equity | ||||||||
Current Liabilities | ||||||||
Accounts payable | $ | 40,556,301 | $ | 26,997,203 | ||||
Accrued payroll | 4,333,786 | 3,508,583 | ||||||
Other accrued liabilities | 5,795,887 | 3,563,843 | ||||||
Related party payable | 443,670 | 988,778 | ||||||
Current portion of operating lease liabilities | 2,491,641 | 1,504,433 | ||||||
Current portion of finance lease liabilities | 1,742,661 | 1,660,404 | ||||||
Notes payable | 116,368 | 814,576 | ||||||
Current portion of long-term debt | 764,766 | 523,510 | ||||||
Total current liabilities | 56,245,080 | 39,561,330 | ||||||
Long-term Liabilities | ||||||||
Revolving line of credit | 10,000,000 | — | ||||||
Operating lease liabilities, net of current portion | 44,372,844 | 28,430,474 | ||||||
Finance lease liabilities, net of current portion | 1,125,607 | 1,455,011 | ||||||
Long-term debt, net of current portion | 14,111,906 | 12,646,049 | ||||||
Warrant liability | 1,416,909 | 1,059,343 | ||||||
Total liabilities | 127,272,346 | 83,152,207 | ||||||
Stockholders' Equity | ||||||||
Common stock; par value | 543,714 | 534,875 | ||||||
Treasury stock | (21,950) | (9,678) | ||||||
Additional paid-in capital | 265,697,111 | 260,978,339 | ||||||
Accumulated deficit | (112,296,636) | (116,483,976) | ||||||
Accumulated other comprehensive loss | (85,385) | (29,136) | ||||||
Total stockholders' equity —Thorne HealthTech, Inc. | 153,836,854 | 144,990,424 | ||||||
Non-controlling interests | 1,418,249 | 1,661,390 | ||||||
Total stockholders' equity | 155,255,103 | 146,651,814 | ||||||
Total liabilities and stockholders' equity | $ | 282,527,449 | $ | 229,804,021 |
Thorne HealthTech, Inc. Condensed Consolidated Statements of Operations (unaudited) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Net sales | $ | 72,714,600 | $ | 54,640,936 | $ | 137,952,379 | $ | 108,670,636 | ||||||||
Cost of sales | 32,077,213 | 24,704,294 | 63,041,402 | 49,254,885 | ||||||||||||
Gross profit | 40,637,387 | 29,936,642 | 74,910,977 | 59,415,751 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 1,506,149 | 1,743,812 | 3,278,238 | 3,711,478 | ||||||||||||
Marketing | 10,037,781 | 15,841,490 | 18,976,472 | 20,642,450 | ||||||||||||
Selling, general and administrative | 22,470,851 | 18,504,691 | 46,048,391 | 36,433,167 | ||||||||||||
Income (loss) from operations | 6,622,606 | (6,153,351) | 6,607,876 | (1,371,344) | ||||||||||||
Other (expense) income, net: | ||||||||||||||||
Interest expense, net | (583,145) | (31,514) | (978,144) | (61,671) | ||||||||||||
Change in fair value of warrant liability | (19,210) | 594,899 | (357,566) | 528,980 | ||||||||||||
Other income (expense), net | 236,787 | (13,761) | 571,318 | 44,094 | ||||||||||||
Total other (expense) income, net | (365,568) | 549,624 | (764,392) | 511,403 | ||||||||||||
Income (loss) before income taxes and gain from equity interests in unconsolidated affiliates | 6,257,038 | (5,603,727) | 5,843,484 | (859,941) | ||||||||||||
Income tax expense | 2,124,000 | 174,553 | 2,153,000 | 207,098 | ||||||||||||
Net income (loss) before gain from equity interests in unconsolidated affiliates | 4,133,038 | (5,778,280) | 3,690,484 | (1,067,039) | ||||||||||||
Gain from equity interests in unconsolidated affiliates | 198,964 | 11,037 | 110,030 | 11,037 | ||||||||||||
Net income (loss) | 4,332,002 | (5,767,243) | 3,800,514 | (1,056,002) | ||||||||||||
Net loss — non-controlling interests | (113,817) | (176,538) | (243,141) | (444,356) | ||||||||||||
Net income (loss) attributable to Thorne HealthTech, Inc. | $ | 4,445,819 | $ | (5,590,705) | $ | 4,043,655 | $ | (611,646) | ||||||||
Earnings (loss) per share: | ||||||||||||||||
Basic | $ | 0.08 | $ | (0.11) | $ | 0.08 | $ | (0.01) | ||||||||
Diluted | $ | 0.08 | $ | (0.11) | $ | 0.08 | $ | (0.01) | ||||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 53,866,857 | 52,731,604 | 53,606,294 | 52,648,653 | ||||||||||||
Diluted | 53,866,857 | 52,731,604 | 53,606,294 | 52,648,653 |
Thorne HealthTech, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) | ||||||||
Six Months Ended June 30, | ||||||||
2023 | 2022 | |||||||
Cash Flows from Operating Activities | ||||||||
Net income (loss) | $ | 3,800,514 | $ | (1,056,002) | ||||
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||||||
Depreciation and amortization | 3,250,840 | 2,865,599 | ||||||
Change in fair value of warrant liability | 357,566 | (528,980) | ||||||
Non-cash lease expense | 1,719,871 | 1,852,780 | ||||||
Stock-based compensation | 6,621,221 | 5,151,248 | ||||||
Amortization of debt issuance cost and debt discount | 86,362 | 1,285 | ||||||
Change in allowance for credit losses | 5,415 | (6,363) | ||||||
Provision for losses on inventories | 266,677 | (157,682) | ||||||
Loss on sale of equipment | 27,233 | — | ||||||
Gain from equity interests in unconsolidated affiliates | (110,029) | (11,037) | ||||||
Write off of related party receivable | 154,696 | — | ||||||
Other non-cash | — | (38,628) | ||||||
Change in operating assets and liabilities | ||||||||
Accounts receivable | (10,900,799) | (5,007,492) | ||||||
Related party receivables | (91,937) | 182,605 | ||||||
Related party payables | (545,108) | (759,905) | ||||||
Inventories | (13,237,252) | (19,321,200) | ||||||
Prepaid expenses and other assets | (3,385,426) | 1,515,266 | ||||||
Accounts payable and accrued liabilities | 19,052,192 | 9,923,479 | ||||||
Accrued payroll | 825,203 | — | ||||||
Other accrued liabilities | 1,164,694 | — | ||||||
Operating lease liabilities | 224,052 | (1,612,862) | ||||||
Net cash provided by (used in) operating activities | 9,285,985 | (7,007,889) | ||||||
Cash Flows from Investing Activities | ||||||||
Purchase of property and equipment | (21,048,631) | (2,226,073) | ||||||
Acquisition of PreCon Health | (4,000,000) | — | ||||||
Acquisition of Nutrativa, net of cash acquired | — | (14,862,287) | ||||||
Purchase of investment in unconsolidated subsidiary | — | (1,000,000) | ||||||
Purchase of license agreements | (375,000) | (375,000) | ||||||
Net cash used in investing activities | (25,423,631) | (18,463,360) | ||||||
Cash Flows from Financing Activities | ||||||||
Proceeds from Revolving Line of Credit | 35,000,000 | — | ||||||
Proceeds from long-term debt - equipment financing | 564,828 | — | ||||||
Payments on Revolving Line of Credit | (25,000,000) | — | ||||||
Payment of long-term debt - equipment financing | (342,673) | (243,475) | ||||||
Payments of notes payable | (698,208) | — | ||||||
Payments on finance lease | (894,332) | (209,514) | ||||||
Buyback of management stock | (1,227,230) | — | ||||||
Debt issuance costs | — | (25,700) | ||||||
Proceeds from issuance of ownership interest in consolidated subsidiary | — | 2,601,806 | ||||||
Stock options exercised | 161,348 | 243,943 | ||||||
Net cash provided by financing activities | 7,563,733 | 2,367,060 | ||||||
Effect of exchange rate changes on cash and restricted cash | (56,249) | (186,200) | ||||||
Net decrease in cash and restricted cash | (8,630,162) | (23,290,389) | ||||||
Cash, cash equivalents and restricted cash, beginning of period | 40,924,847 | 56,000,915 | ||||||
Cash, cash equivalents and restricted cash, end of period | $ | 32,294,685 | $ | 32,710,526 |
Thorne HealthTech, Inc. Reconciliations of Non-GAAP Financial Measures (unaudited) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Net income (loss) attributable to Thorne HealthTech, Inc. | $ | 4,445,819 | $ | (5,590,705) | $ | 4,043,655 | $ | (611,646) | |||||||
Gain from equity interests in unconsolidated affiliates | (113,817) | (176,538) | (243,141) | (444,356) | |||||||||||
Net income (loss) before gain from equity interests in unconsolidated affiliates | $ | 4,332,002 | $ | (5,767,243) | $ | 3,800,514 | $ | (1,056,002) | |||||||
EBITDA and Adjusted EBITDA Reconciliation | |||||||||||||||
Net income (loss) | $ | 4,332,002 | $ | (5,767,243) | $ | 3,800,514 | $ | (1,056,002) | |||||||
Net income (loss) margin | 6.0 | % | (10.6) | % | 2.8 | % | (1.0) | % | |||||||
Depreciation and amortization | 1,689,821 | 1,523,749 | 3,250,840 | 2,865,599 | |||||||||||
Interest expense, net | 583,145 | 31,514 | 978,144 | 61,671 | |||||||||||
Income tax expense | 2,124,000 | 174,553 | 2,153,000 | 207,098 | |||||||||||
EBITDA | 8,728,968 | (4,037,427) | 10,182,498 | 2,078,366 | |||||||||||
EBITDA margin | 12.0 | % | (7.4) | % | 7.4 | % | 1.9 | % | |||||||
Adjustments: | |||||||||||||||
Stock-based compensation | 2,873,086 | 3,141,836 | 6,621,221 | 5,151,248 | |||||||||||
Non-cash lease expense | 546,459 | 107,113 | 1,037,627 | 216,017 | |||||||||||
Change in fair value of warrant liability | 19,210 | (594,899) | 357,566 | (528,980) | |||||||||||
Gain from equity interests in unconsolidated affiliates | (198,964) | (11,037) | (110,030) | (11,037) | |||||||||||
Transaction-related costs | 566,038 | 58,825 | 566,038 | 519,236 | |||||||||||
Adjusted EBITDA | $ | 12,534,797 | $ | (1,335,589) | $ | 18,654,920 | $ | 7,424,850 | |||||||
Adjusted EBITDA Margin | 17.2 | % | (2.4) | % | 13.5 | % | 6.8 | % | |||||||
Adjusted Net Income (Loss) Reconciliation | |||||||||||||||
Net income (loss) | 4,332,002 | (5,767,243) | 3,800,514 | (1,056,002) | |||||||||||
Income tax expense | 2,124,000 | 174,553 | 2,153,000 | 207,098 | |||||||||||
Stock-based compensation | 2,873,086 | 3,141,836 | 6,621,221 | 5,151,248 | |||||||||||
Non-cash lease expense | 546,459 | 107,113 | 1,037,627 | 216,017 | |||||||||||
Change in fair value of warrant liability | 19,210 | (594,899) | 357,566 | (528,980) | |||||||||||
Gain from equity interests in unconsolidated affiliates | (198,964) | (11,037) | (110,030) | (11,037) | |||||||||||
Transaction-related costs | 566,038 | 58,825 | 566,038 | 519,236 | |||||||||||
Adjusted net income (loss) before adjusted tax expense | 10,261,831 | (2,890,852) | 14,425,936 | 4,497,580 | |||||||||||
Adjusted income tax expense (benefit) | 2,213,659 | (289,085) | 3,296,326 | 449,758 | |||||||||||
Adjusted net income (loss) | $ | 8,048,172 | $ | (2,601,767) | $ | 11,129,610 | $ | 4,047,822 | |||||||
Diluted weighted-average shares outstanding | 53,866,857 | 52,731,604 | 53,606,294 | 52,648,653 | |||||||||||
Adjusted diluted earnings (loss) per share | $ | 0.15 | $ | (0.05) | $ | 0.21 | $ | 0.08 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/thorne-healthtech-reports-second-quarter-2023-results-301896121.html
SOURCE Thorne HealthTech, Inc.
FAQ
What is the ticker symbol for Thorne HealthTech, Inc.?
What were the net sales for Thorne HealthTech, Inc. in the second quarter of 2023?
What is the adjusted EBITDA for Thorne HealthTech, Inc. in the second quarter of 2023?
What is the CE Mark certification earned by Thorne HealthTech, Inc.?
What is the full-year guidance range for net sales provided by Thorne HealthTech, Inc.?